Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs AMG 594 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Amgen
- 09 May 2019 According to a Cytokinetics media release, the company expects the conduct of this study to continue throughout 2019.
- 20 Feb 2019 Status changed from planning to recruiting, according to a Cytokinetics media release.
- 20 Feb 2019 According to a Cytokinetics media release, first patient has been dosed in this study.